Marketing-authorisation holder
Mitsubishi Tanabe Pharma GmbH
2 medicines in 2 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
2 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Onerji (60 mg + 7,5 mg)/ml oplossing voor infusieOplossing voor infusie | Carbidopa, Levodopa | Netherlands | Authorised | 2026 |
| Radicava | Edaravone | EU (EMA) | Refused |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 1 | 0 | 1 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.